Miami in March is not just warm weather and ocean views. For the global biotech community, it has become one of the most important annual gathering points — and Korea sent a delegation.
The BIG Summit (Biotech Innovation Gateway) brought together over 400 life sciences professionals from 12 countries. Among them, a growing contingent of Korean biotech founders, many attending for the first time, seeking to understand the path from Korean laboratory to American hospital bedside.
The real barrier for Korean biotech in the US is not language — it is regulatory navigation. FDA approval pathways, clinical trial design for American populations, intellectual property strategy in a litigious market. These were the sessions where Korean founders took the most notes.
Formal sessions matter, but the hallway conversations at BIG Summit told a different story. Korean founders who arrived with pitch decks left with something more valuable: introductions to the regulatory consultants, patent attorneys, and clinical research organizations that form the invisible infrastructure of US market entry.
KORISE will continue covering the Korea-US biotech corridor as it develops, summit by summit, deal by deal.